Maternal-Fetal RelationsTRANSFERTNCT06480916
Study of the Value of Maternal-fetal Transfers and Their Complexity of Their Implementation
An observational study of Maternal-Fetal Relations, run by Centre Hospitalier Régional Metz-Thionville at 8 sites in France.
Trial summary
It is an observational, descriptive, prospective, multicenter study of 8 maternity units in Lorraine and Champagne-Ardenne, aimed at comparing the percentage of "avoidable" maternal-fetal transfers (MFTs), defined as transfers in which the delivery finally meets the acceptance criteria of the sending maternity unit… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Maternal-Fetal Relations
- What is being tested?
- Maternal-fetal transfers
- Type of treatment
- Surgery or procedure
- How many people
- 101 participants
- Where
- 8 sitesFrance
- Study dates
- 1 Apr 2024to 1 Apr 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Maternal-fetal transfers (MFTs) for threatened premature delivery
Who may be able to join
- Pregnant woman cared for in a participating maternity unit
- Over 18 years of age
- Requested for maternal-fetal transfer (finally performed, or not)
Who cannot join
- missing data on transfer outcome
Trial locations and contacts
8 sites in 1 country.
8 sites in 1 country
France8 sites
Hopital Maillot
Briey
Maternité CH Léon Bourgeois
Châlons-en-Champagne
CHR Metz Thionville Hopital Femme Mère Enfant
Metz, 57085
Maternité - Hôpital Maurice Camuset
Romilly-sur-Seine
Clinique Saint Nabor
Saint-Avold
Matérnité Saint Dizier
Saint-Dizier
CHR Metz-Thionville Hopital Bel Air
Thionville
Hopital Saint Nicolas
Verdun
About this study
It is an observational, descriptive, prospective, multicenter study of 8 maternity units in Lorraine and Champagne-Ardenne, aimed at comparing the percentage of "avoidable" maternal-fetal transfers (MFTs), defined as transfers in which the delivery finally meets the acceptance criteria of the sending maternity unit, according to the obstetrical indications for these MFTs.
Read the detailed description
Over the past year, an audit carried out on the Mercy maternity unit, covering 130 transfers to the Nancy regional maternity hospital, showed that patients transferred for threat of premature delivery (MAP) with a cervix > 15 mm do not give birth at the receiving maternity unit, but return home after 48 hours' hospitalization.
When maternal-fetal transfer (MFT) is requested, numerous calls are made to private ambulance services, and in the end, many emergency rapid response units (SMUR) are called out, requiring a major human, logistical and time investment for a questionable benefit to the patient. Tensions in terms of logistics (lack of ambulance, SMUR) and human resources (lack of personnel) can, conversely, compromise good care of the parturient.
- Conditions
- Maternal-Fetal Relations
- Being tested
- Maternal-fetal transfers
- Keywords
- maternal-fetal transfer, care organization, patient pathway, maternity hospital
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Maternal-fetal transfersProcedure or surgery
Prospective and consecutive inclusion of all maternal-fetal transfers during the study period. The teams at the sending and receiving maternity units will complete study-related questionnaires to describe the conditions of the transfer and the outcome of the pregnancy. The study in no way alters the way parturients are cared for.
What is being measured
The primary outcome is the main question the study is designed to answer.
The percentage of "avoidable" maternal-foetal transfer (MFT)
The main evaluation criterion is "avoidable" maternal-foetal transfer (MFT), i.e. resulting in a delivery that met the acceptance criteria of the original maternity hospital
Measured: after delivery, up to 6 weeks after the maternal-foetal transfer
Secondary outcomes (2)
Obstetrical indication for maternal-foetal transfer (MFT)
as documented in the patient file
Measured: Up to 48 hours after the maternal-foetal transfer
Organizational arrangements for maternal-foetal transfer
Organizational arrangements for maternal-foetal transfer in the various centers, assessed by a specific questionnaire sent to maternity units.
Measured: Up to 6 months after inclusion of a maternity unit in the study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jun 2024
- Study start1 Apr 2024
- Primary completion1 Apr 2025
- Study completion1 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Maternal-Fetal RelationsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 101 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Régional Metz-Thionville
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Laetitia HONORE-ROUGE, MD, Principal investigator, CHR Metz Thionville Hopital Femme Mère Enfant
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06480916
- Sponsor's protocol ID
- 2024-04Obs-CHRMT
- Acronym
- TRANSFERT
- Status last verified
- Jun 2026
- First submitted
- 19 Jun 2024
- Last updated
- 24 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Value of Maternal-fetal Transfers and Their Complexity of Their Implementation
- ClinicalTrials.gov ID
- NCT06480916
- Acronym / sponsor ID
- TRANSFERT / 2024-04Obs-CHRMT
- Conditions
- Maternal-Fetal Relations
- Keywords
- maternal-fetal transfer, care organization, patient pathway, maternity hospital
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 101 participants (actual)
- Lead sponsor
- Centre Hospitalier Régional Metz-ThionvilleUniversity, hospital or other
- Study start
- 1 Apr 2024 (actual)
- Primary completion
- 1 Apr 2025 (actual)
- Study completion
- 1 Apr 2025 (actual)
- First posted
- 28 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is an observational, descriptive, prospective, multicenter study of 8 maternity units in Lorraine and Champagne-Ardenne, aimed at comparing the percentage of "avoidable" maternal-fetal transfers (MFTs), defined as transfers in which the delivery finally meets the acceptance criteria of the sending maternity unit, according to the obstetrical indications for these MFTs.
Detailed description
Over the past year, an audit carried out on the Mercy maternity unit, covering 130 transfers to the Nancy regional maternity hospital, showed that patients transferred for threat of premature delivery (MAP) with a cervix > 15 mm do not give birth at the receiving maternity unit, but return home after 48 hours' hospitalization.
When maternal-fetal transfer (MFT) is requested, numerous calls are made to private ambulance services, and in the end, many emergency rapid response units (SMUR) are called out, requiring a major human, logistical and time investment for a questionable benefit to the patient. Tensions in terms of logistics (lack of ambulance, SMUR) and human resources (lack of personnel) can, conversely, compromise good care of the parturient.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Maternal-fetal transfers (MFTs) for threatened premature delivery
Key inclusion criteria (3 listed)
- Pregnant woman cared for in a participating maternity unit
- Over 18 years of age
- Requested for maternal-fetal transfer (finally performed, or not)
Key exclusion criteria (1 listed)
- missing data on transfer outcome
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Maternal-fetal transfersProspective and consecutive inclusion of all maternal-fetal transfers during the study period. The teams at the sending and receiving maternity units will complete study-related questionnaires to describe the conditions of the transfer and the outcome of the pregnancy. The study in no way alters the way parturients are cared for. | Procedure or surgery | – |
Primary outcome
The percentage of "avoidable" maternal-foetal transfer (MFT)
Time frame: after delivery, up to 6 weeks after the maternal-foetal transfer
The main evaluation criterion is "avoidable" maternal-foetal transfer (MFT), i.e. resulting in a delivery that met the acceptance criteria of the original maternity hospital
2 secondary outcomes
Obstetrical indication for maternal-foetal transfer (MFT)
Time frame: Up to 48 hours after the maternal-foetal transfer
Organizational arrangements for maternal-foetal transfer
Time frame: Up to 6 months after inclusion of a maternity unit in the study
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Maternal-Fetal Relations
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingObservational study
Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy
Pregnancy Related
RecruitingObservational study
Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Pregnancy Related
RecruitingObservational study
Maternal Cancer Diagnosis and Treatment During Pregnancy:a Database for Maternal, Fetal, and Neonatal Outcomes
Pregnancy, Cancer, Cancer in Pregnancy, Gestational Breast Cancer, Pregnancy Related
RecruitingObservational study
Fetal Health Locus of Control, Maternal Anxiety, and Cardiotocography in High-Risk Pregnancies
High-risk Pregnancy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Laetitia HONORE-ROUGE, MD principal investigator
CHR Metz Thionville Hopital Femme Mère Enfant
8 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Maternal-Fetal Relations, run by Centre Hospitalier Régional Metz-Thionville at 8 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The percentage of "avoidable" maternal-foetal transfer (MFT) (time frame: after delivery, up to 6 weeks after the maternal-foetal transfer). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2026.